ERBB2 and neoplasm: Those patients with HER2-positive tumours and high SK1 expression have a mean disease-free survival of 2.9 years and a mean disease-specific survival time of 4.1 years compared with 6.45 years for disease-free survival and 12 years for disease-specific survival in the low tumour SK1 expression group.